文献速递头痛与眩晕

Erenumab治疗发作性偏头痛的长期疗效与安全性:LIBERTY研究64周结果

Long-term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY Study.
PubMed 文献 · Neurology · 2021-05-31

LIBERTY研究开放标签扩展期评估每月erenumab 140 mg治疗发作性偏头痛(EM)患者(既往2-4种预防治疗失败)的疗效与安全性。至第64周,持续erenumab组50%应答率从29.9%升至44.3%,开放标签期起始erenumab组从14.2%升至50.0%,安全性与此前试验一致。

要点

  • 既往2-4种预防治疗失败的EM患者,erenumab单药治疗至64周仍持续有效。
  • 持续治疗组50%应答率从29.9%(第9-12周)升至44.3%(第61-64周)。
  • 开放标签期起始组50%应答率从14.2%(第9-12周)升至50.0%(第61-64周)。

核心结论

  • 在既往2-4种预防治疗失败的发作性偏头痛患者中,erenumab单药治疗至64周在两个治疗组均显示持续疗效。
  • Erenumab的安全性与此前临床试验中观察到的结果一致。

研究设计与样本

  • LIBERTY研究(NCT03096834)开放标签扩展期(OLEP),评估每月erenumab 140 mg治疗3年。
  • 纳入完成12周双盲治疗期(DBTP)的240例患者,DBTP期间接受安慰剂或erenumab 140 mg皮下注射每4周一次单药治疗。
  • 疗效评估至OLEP初始52周(从DBTP基线至总计64周),分析总体人群、DBTP接受erenumab者及DBTP安慰剂组在OLEP换用erenumab者。

主要发现

  • OLEP第52周访视完成204/240例(85.0%)。
  • 持续erenumab组50%应答率从第9-12周的29.9%升至第61-64周的44.3%。
  • OLEP起始erenumab组50%应答率在第61-64周为50.0%,高于DBTP第9-12周的14.2%。
  • 总体人群50%应答率从第13-16周升至第37-40周,之后至第61-64周保持稳定。
  • DBTP接受erenumab者所有疗效结局持续有效;OLEP起始erenumab者自第13周起持续改善。

关键数值与推荐

  • 持续erenumab组不良事件(AE)发生率约80.8%(严重AE 6.7%),OLEP起始erenumab组85.2%(严重AE 7.4%)。
  • 未报告死亡。

临床怎么用

  • 对于既往多种预防治疗失败的发作性偏头痛患者,erenumab单药治疗可考虑作为长期预防选择。
  • 治疗期间需监测不良事件,严重不良事件发生率较低。

局限性

  • 本研究为开放标签扩展期,证据等级为Class IV。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report the efficacy and safety of erenumab among patients with episodic migraine (EM) who were unsuccessful on 2 to 4 preventive treatments observed at week 64 of the open-label extension phase (OLEP) of A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies (LIBERTY) study (ClinicalTrials.gov NCT03096834). METHODS: The OLEP, evaluating monthly erenumab 140 mg for 3 years, enrolled 240 patients who completed the double-blind treatment phase (DBTP) of 12 weeks during which they received placebo or erenumab 140 mg subcutaneous injections every 4 weeks as monotherapy. Efficacy outcomes were evaluated through the initial 52 weeks of OLEP (from DBTP baseline to total 64 weeks) in the overall population, patients receiving erenumab in DBTP, and patients from the DBTP placebo arm who switched to erenumab in OLEP. Endpoints included reduction of ≥50% in monthly migraine days (MMD) from DBTP baseline and change in MMD from DBTP baseline, Headache Impact Test score, and Migraine Physical Function Impact Diary score (Physical Impairment and Everyday Activities). RESULTS: Altogether, the week 52 visit of the OLEP was completed by 204 of 240 (85.0%) patients. Among patients continuing erenumab, the 50% responder rate increased from 29.9% at weeks 9 to 12 to 44.3% at weeks 61 to 64. The 50% responder rate in patients who initiated erenumab in the OLEP remained higher in the OLEP (50.0% at week 61-64) than during DBTP (14.2% at weeks 9-12) compared to patients in continuous erenumab arm. In the OLEP, the 50% responder rate for the overall population increased from weeks 13 to 16 until weeks 37 to 40 and then remained stable through weeks 61 to 64. Patients treated with erenumab in DBTP showed sustained effects on all efficacy outcomes; those initiating erenumab in the OLEP demonstrated continued improvement from week 13 onward. Adverse events (AEs) were reported, considering both treatment groups, by ≈80.8% (serious AEs by 6.7%), 76.3% (5.9%) in the continuing erenumab arm, and 85.2% (7.4%) in those starting erenumab in OLEP. No deaths were reported. CONCLUSIONS: In patients with EM who were unsuccessful on 2 to 4 prior preventive treatments, the LIBERTY study demonstrated sustained efficacy on erenumab monotherapy treatment through 64 weeks in both treatment arms. Safety of erenumab was consistent with that observed in previous clinical trials. TRIAL REGISTRATION INFORMATION: ClinicalTrials.govIdentifier: NCT03096834. CLASSIFICATION OF EVIDENCE: The current study provides Class IV evidence on data from patients with EM that erenumab is safe and provides sustained efficacy at 52 weeks.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Goadsby PJ, Reuter U, Lanteri-Minet M, et al. Long-term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY Study. Neurology. 2021. PMID: 33910942. doi:10.1212/WNL.0000000000012029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。